Advertisement


Natalie Moryl, MD, on Managing Pain in Patients With Cancer

NCCN 2023 Annual Conference

Advertisement

Natalie Moryl, MD, of Memorial Sloan Kettering Cancer Center, discusses severe cancer pain, a medical emergency that should be addressed with immediate intervention. The treatment plan, Dr. Moryl says, should include making a pain diagnosis; addressing reversible causes of pain such as spinal cord compression, fracture, or obstruction; selecting, titrating, and rotating opioids and co-analgesics; and routine screening for risks of opioid use disorder and mental health comorbidities.



Related Videos

Solid Tumors
Lung Cancer

Ella A. Kazerooni, MD, on Lung Cancer Screening: Benefits and Challenges

Ella A. Kazerooni, MD, of the University of Michigan Rogel Cancer Center, discusses reducing cancer deaths in the United States by identifying patients at risk for lung cancer. Engaging with primary care physicians and facilitating referrals are keys to a successful lung cancer screening program, she says, as is working with a nurse care coordinator.

CNS Cancers
Solid Tumors

Louis B. Nabors, MD, on NCCN Clinical Practice Guidelines in Oncology Updates for CNS Cancers in Adults

Louis B. Nabors, MD, of the O’Neal Comprehensive Cancer Center at UAB, discusses the three subtypes of adult gliomas classified by the World Health Organization, treatments influenced by IDH mutation status, the roles of radiotherapy and chemotherapy, molecular testing, and pseudoprogression and RANO (response assessment in neuro-oncology) criteria.

Issues in Oncology

Mandi L. Pratt-Chapman, PhD, on Oncology Care in the LGBTQI+ Community: Best Practices for Addressing Health Needs

Mandi L. Pratt-Chapman, PhD, of the George Washington University Cancer Center, discusses the specific health-care needs for cancer screening, treatment, and survivorship among members of the LGBTQI+ community. Because clinical practices and research studies do not routinely collect sexual orientation and gender identity data, there is insufficient evidence to guide clinical care decision-making, Dr. Pratt-Chapman says.

Solid Tumors
Colorectal Cancer

Midhun Malla, MD, on Metastatic Colorectal Cancer: Treatment Updates

Midhun Malla, MD, of the West Virginia University Cancer Institute, discusses the molecular landscape of metastatic colorectal cancer and the development and approvals of targeted treatments. Dr. Malla also details the range of HER2-targeted therapeutic options and the approval of trastuzumab and tucatinib for HER2-amplified disease in the second-line setting or after. In addition, he discusses emerging therapies in refractory metastatic colorectal cancers followed by circulating tumor DNA–guided management of oligometastatic colorectal cancers using immune checkpoint inhibitors.

Solid Tumors
Bladder Cancer

Arlene O. Siefker-Radtke, MD, on Urothelial Cancer: Emerging Therapies

Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, provides an overview of the emerging treatments for urothelial cancer, including several new agents in the antibody-drug conjugate and tyrosine kinase inhibitor classes. She describes the clinical activity and toxicities of enfortumab vedotin-ejfv, erdafitinib, and sacituzumab govitecan-hziy.

Advertisement

Advertisement



Advertisement